Soft Tissue Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major soft tissue neoplasms markets are expected to exhibit a CAGR of 6.07% during 2024-2034.
The soft tissue neoplasms market has been comprehensively analyzed in IMARC's new report titled "Soft Tissue Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Soft tissue neoplasms are a group of cancerous or non-cancerous tumors that develop in the soft tissues of the body. Soft tissues refer to the connective cells that support and surround organs, muscles, blood vessels, nerves, as well as several other structures. The tumors can arise from different types of cells found in the soft tissues and exhibit a wide range of behavior, from slow-growing and localized to aggressive and metastatic. Some common signs and symptoms associated with this ailment include a palpable mass or lump, pain or discomfort in the affected area, swelling, limited range of motion, numbness, tingling, weakness, fatigue, unexplained weight loss, ulceration, skin discoloration, etc. The diagnosis of soft tissue neoplasms typically involves a combination of clinical assessment, medical history review, and pathological analysis. Various imaging techniques, such as X-rays, magnetic resonance imaging, positron emission tomography scans, etc., can be used to visualize the tumor and identify its characteristic findings. The healthcare provider may further perform a tissue biopsy to confirm the diagnosis among patients.
The increasing cases of genetic conditions, which can result in the production of abnormal fusion genes and defective proteins, are primarily driving the soft tissue neoplasms market. In addition to this, the rising prevalence of trauma or injury to the soft tissues that can lead to cellular damage and inflammation is also creating a positive outlook for the market. Moreover, the widespread adoption of high-energy radiation therapy to provide local tumor control by directly targeting unhealthy tissues is further bolstering the market growth. Apart from this, the escalating application of immunotherapy drugs, since they can stimulate the body's defense system to recognize and attack cancerous cells, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive methods, including cryoablation techniques, owing to their various benefits, like less postoperative pain, fewer wound-related issues, and a shorter hospital stay, is also augmenting the market growth. Furthermore, the inflating utilization of embolization, which involves injecting small particles or beads into the blood vessels feeding the tumors, causing them to shrink, is expected to drive the soft tissue neoplasms market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the soft tissue neoplasms market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for soft tissue neoplasms and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the soft tissue neoplasms market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the soft tissue neoplasms market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the soft tissue neoplasms market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current soft tissue neoplasms marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the soft tissue neoplasms market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the soft tissue neoplasms market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the soft tissue neoplasms market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of soft tissue neoplasms across the seven major markets?
What is the number of prevalent cases (2018-2034) of soft tissue neoplasms by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of soft tissue neoplasms by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with soft tissue neoplasms across the seven major markets?
What is the size of the soft tissue neoplasms patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of soft tissue neoplasms?
What will be the growth rate of patients across the seven major markets?
Soft Tissue Neoplasms: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for soft tissue neoplasms drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the soft tissue neoplasms market?
What are the key regulatory events related to the soft tissue neoplasms market?
What is the structure of clinical trial landscape by status related to the soft tissue neoplasms market?
What is the structure of clinical trial landscape by phase related to the soft tissue neoplasms market?
What is the structure of clinical trial landscape by route of administration related to the soft tissue neoplasms market?
The soft tissue neoplasms market has been comprehensively analyzed in IMARC's new report titled "Soft Tissue Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Soft tissue neoplasms are a group of cancerous or non-cancerous tumors that develop in the soft tissues of the body. Soft tissues refer to the connective cells that support and surround organs, muscles, blood vessels, nerves, as well as several other structures. The tumors can arise from different types of cells found in the soft tissues and exhibit a wide range of behavior, from slow-growing and localized to aggressive and metastatic. Some common signs and symptoms associated with this ailment include a palpable mass or lump, pain or discomfort in the affected area, swelling, limited range of motion, numbness, tingling, weakness, fatigue, unexplained weight loss, ulceration, skin discoloration, etc. The diagnosis of soft tissue neoplasms typically involves a combination of clinical assessment, medical history review, and pathological analysis. Various imaging techniques, such as X-rays, magnetic resonance imaging, positron emission tomography scans, etc., can be used to visualize the tumor and identify its characteristic findings. The healthcare provider may further perform a tissue biopsy to confirm the diagnosis among patients.
The increasing cases of genetic conditions, which can result in the production of abnormal fusion genes and defective proteins, are primarily driving the soft tissue neoplasms market. In addition to this, the rising prevalence of trauma or injury to the soft tissues that can lead to cellular damage and inflammation is also creating a positive outlook for the market. Moreover, the widespread adoption of high-energy radiation therapy to provide local tumor control by directly targeting unhealthy tissues is further bolstering the market growth. Apart from this, the escalating application of immunotherapy drugs, since they can stimulate the body's defense system to recognize and attack cancerous cells, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive methods, including cryoablation techniques, owing to their various benefits, like less postoperative pain, fewer wound-related issues, and a shorter hospital stay, is also augmenting the market growth. Furthermore, the inflating utilization of embolization, which involves injecting small particles or beads into the blood vessels feeding the tumors, causing them to shrink, is expected to drive the soft tissue neoplasms market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the soft tissue neoplasms market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for soft tissue neoplasms and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the soft tissue neoplasms market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the soft tissue neoplasms market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the soft tissue neoplasms market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current soft tissue neoplasms marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the soft tissue neoplasms market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the soft tissue neoplasms market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the soft tissue neoplasms market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of soft tissue neoplasms across the seven major markets?
What is the number of prevalent cases (2018-2034) of soft tissue neoplasms by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of soft tissue neoplasms by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with soft tissue neoplasms across the seven major markets?
What is the size of the soft tissue neoplasms patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of soft tissue neoplasms?
What will be the growth rate of patients across the seven major markets?
Soft Tissue Neoplasms: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for soft tissue neoplasms drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the soft tissue neoplasms market?
What are the key regulatory events related to the soft tissue neoplasms market?
What is the structure of clinical trial landscape by status related to the soft tissue neoplasms market?
What is the structure of clinical trial landscape by phase related to the soft tissue neoplasms market?
What is the structure of clinical trial landscape by route of administration related to the soft tissue neoplasms market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOFT TISSUE NEOPLASMS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SOFT TISSUE NEOPLASMS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SOFT TISSUE NEOPLASMS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SOFT TISSUE NEOPLASMS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SOFT TISSUE NEOPLASMS - UNMET NEEDS
10 SOFT TISSUE NEOPLASMS - KEY ENDPOINTS OF TREATMENT
11 SOFT TISSUE NEOPLASMS - MARKETED PRODUCTS
11.1 List of Soft Tissue Neoplasms Marketed Drugs Across the Top 7 Markets
11.1.1 Lartruvo (Olaratumab) - Eli Lilly and Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Votrient (Pazopanib) - GlaxoSmithKline/Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Yondelis (Trabectedin) - Johnson & Johnson
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SOFT TISSUE NEOPLASMS - PIPELINE DRUGS
12.1 List of Soft Tissue Neoplasms Pipeline Drugs Across the Top 7 Markets
12.1.1 L19TNF - Philogen
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Annamycin liposomal - Moleculin Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AL3818 - Advenchen Laboratories
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 GPX150 - Monopar Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SOFT TISSUE NEOPLASMS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SOFT TISSUE NEOPLASMS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SOFT TISSUE NEOPLASMS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Soft Tissue Neoplasms - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Soft Tissue Neoplasms - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Soft Tissue Neoplasms - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Soft Tissue Neoplasms - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Soft Tissue Neoplasms - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Soft Tissue Neoplasms - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Soft Tissue Neoplasms - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Soft Tissue Neoplasms - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Soft Tissue Neoplasms - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Soft Tissue Neoplasms - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Soft Tissue Neoplasms - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Soft Tissue Neoplasms - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Soft Tissue Neoplasms - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Soft Tissue Neoplasms - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Soft Tissue Neoplasms - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Soft Tissue Neoplasms - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
16 SOFT TISSUE NEOPLASMS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SOFT TISSUE NEOPLASMS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SOFT TISSUE NEOPLASMS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOFT TISSUE NEOPLASMS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SOFT TISSUE NEOPLASMS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SOFT TISSUE NEOPLASMS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SOFT TISSUE NEOPLASMS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SOFT TISSUE NEOPLASMS - UNMET NEEDS
10 SOFT TISSUE NEOPLASMS - KEY ENDPOINTS OF TREATMENT
11 SOFT TISSUE NEOPLASMS - MARKETED PRODUCTS
11.1 List of Soft Tissue Neoplasms Marketed Drugs Across the Top 7 Markets
11.1.1 Lartruvo (Olaratumab) - Eli Lilly and Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Votrient (Pazopanib) - GlaxoSmithKline/Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Yondelis (Trabectedin) - Johnson & Johnson
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SOFT TISSUE NEOPLASMS - PIPELINE DRUGS
12.1 List of Soft Tissue Neoplasms Pipeline Drugs Across the Top 7 Markets
12.1.1 L19TNF - Philogen
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Annamycin liposomal - Moleculin Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AL3818 - Advenchen Laboratories
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 GPX150 - Monopar Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SOFT TISSUE NEOPLASMS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SOFT TISSUE NEOPLASMS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SOFT TISSUE NEOPLASMS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Soft Tissue Neoplasms - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Soft Tissue Neoplasms - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Soft Tissue Neoplasms - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Soft Tissue Neoplasms - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Soft Tissue Neoplasms - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Soft Tissue Neoplasms - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Soft Tissue Neoplasms - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Soft Tissue Neoplasms - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Soft Tissue Neoplasms - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Soft Tissue Neoplasms - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Soft Tissue Neoplasms - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Soft Tissue Neoplasms - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Soft Tissue Neoplasms - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Soft Tissue Neoplasms - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Soft Tissue Neoplasms - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Soft Tissue Neoplasms - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Soft Tissue Neoplasms - Access and Reimbursement Overview
16 SOFT TISSUE NEOPLASMS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SOFT TISSUE NEOPLASMS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SOFT TISSUE NEOPLASMS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
